|
US5395842A
(en)
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
|
US5686465A
(en)
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
|
US5254568A
(en)
|
1990-08-09 |
1993-10-19 |
Council Of Scientific & Industrial Research |
Benzopyrans as antiestrogenic agents
|
|
EP0470310B1
(en)
|
1990-08-09 |
1995-11-29 |
Council of Scientific and Industrial Research |
Novel benzopyrans and process for their production
|
|
US6060503A
(en)
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
ES2105525T3
(es)
|
1993-06-24 |
1997-10-16 |
Lilly Co Eli |
2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
|
|
US5407947A
(en)
*
|
1993-11-05 |
1995-04-18 |
Eli Lilly And Company |
Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
|
|
US5446061A
(en)
|
1993-11-05 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5416098A
(en)
|
1993-12-30 |
1995-05-16 |
Zymogenetics, Inc. |
Method for treating dermatitis and related conditions
|
|
US5389646A
(en)
|
1993-12-30 |
1995-02-14 |
Zymogenetics, Inc. |
Methods for treatment and prevention of bone loss using 2,3-benzopyrans
|
|
US5681835A
(en)
|
1994-04-25 |
1997-10-28 |
Glaxo Wellcome Inc. |
Non-steroidal ligands for the estrogen receptor
|
|
UA41909C2
(uk)
|
1994-07-22 |
2001-10-15 |
Елі Ліллі Енд Компані |
Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
|
|
US5446071A
(en)
|
1994-11-18 |
1995-08-29 |
Eli Lilly And Company |
Methods for lowering serum cholesterol
|
|
US5637598A
(en)
|
1994-11-18 |
1997-06-10 |
Eli Lilly And Company |
Methods of inhibiting bone loss
|
|
US5980938A
(en)
|
1996-07-15 |
1999-11-09 |
Eli Lilly And Company |
Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
|
|
WO1998018776A1
(en)
*
|
1996-10-28 |
1998-05-07 |
Novo Nordisk A/S |
Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
|
|
WO1999002513A1
(en)
|
1997-07-09 |
1999-01-21 |
Novo Nordisk A/S |
Preparation of diaryl-benzopyrans
|
|
AU8102398A
(en)
|
1997-07-09 |
1999-02-08 |
Central Drug Research Institute |
(dl)-2,3-diaryl-2h-1-benzopyrans
|
|
BR9811946A
(pt)
|
1997-08-15 |
2000-08-22 |
Univ Duke |
Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
|
|
US6326392B1
(en)
|
1997-11-06 |
2001-12-04 |
American Home Products Corporation |
Anti-estrogen plus progestin containing oral contraceptives
|
|
ID24568A
(id)
|
1997-11-06 |
2000-07-27 |
American Home Prod |
Kontrasepsi oral yang mengandung anti-estrogen plus progestin
|
|
CA2323575A1
(en)
|
1998-03-30 |
1999-11-25 |
Regents Of The University Of California |
Methods and compounds for modulating nuclear receptor coactivator binding
|
|
KR20010042373A
(ko)
|
1998-03-30 |
2001-05-25 |
린다 에스. 스티븐슨 |
핵 수용체 활성을 조절하는 방법 및 화합물
|
|
US7005428B1
(en)
|
1998-06-11 |
2006-02-28 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
|
DE69905376T2
(de)
|
1998-08-14 |
2003-10-09 |
Schering Corp., Kenilworth |
Enanthioauswählende synthese
|
|
US6262270B1
(en)
|
1998-08-14 |
2001-07-17 |
Schering Corporation |
Enantioselective synthesis
|
|
WO2000037083A1
(en)
|
1998-12-18 |
2000-06-29 |
Schering Corporation |
Oral antiestrogen pharmaceutical composition
|
|
US6638727B1
(en)
|
1999-01-26 |
2003-10-28 |
Cytyc Health Corporation |
Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
|
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
DE19916419B4
(de)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
|
|
TR200502284T2
(tr)
|
1999-07-06 |
2005-08-22 |
Endorecherche, Inc. |
Kilo alımını tedavi ve/veya önleme metotları
|
|
WO2001026651A2
(en)
|
1999-10-14 |
2001-04-19 |
Endorecherche, Inc. |
Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
CO5271696A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Procedimiento para reducir la morbilidad y el riesgo de mortalidad
|
|
CO5271709A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
|
|
CO5251465A1
(es)
|
2000-01-26 |
2003-02-28 |
Pfizer Prod Inc |
Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
|
|
CN1400904A
(zh)
|
2000-01-28 |
2003-03-05 |
恩多研究公司 |
与雌激素联合的选择性雌激素受体调节剂
|
|
WO2001063292A2
(en)
|
2000-02-22 |
2001-08-30 |
Board Of Regents, The University Of Texas System |
Compositions and methods of use of het, a novel modulator of estrogen action
|
|
DE10013782A1
(de)
*
|
2000-03-15 |
2001-10-18 |
Schering Ag |
4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
US6528681B2
(en)
|
2000-04-05 |
2003-03-04 |
Bristol-Meyers Squibb Pharma Company |
Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
|
|
US20020013327A1
(en)
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
US7863011B2
(en)
|
2000-05-10 |
2011-01-04 |
Signe Biopharma, Inc. |
Screening method for predicting susceptibility to breast cancer
|
|
US8119138B2
(en)
|
2000-05-10 |
2012-02-21 |
Signe Biopharma Inc. |
Anti-estrogen and immune modulator combinations for treating breast cancer
|
|
EP1177787A3
(en)
|
2000-07-28 |
2003-09-10 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating cataracts
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
US20020099013A1
(en)
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
|
CN1729002A
(zh)
|
2000-09-08 |
2006-02-01 |
法玛西雅意大利公司 |
依西美坦作为化学预防剂
|
|
EP1192945A3
(en)
|
2000-09-21 |
2004-03-03 |
Pfizer Products Inc. |
Use of an estrogen agonist/antagonist for treating osteoarthritis
|
|
PL361874A1
(en)
|
2000-10-06 |
2004-10-04 |
Biomedicines, Inc. |
Combination therapy for the treatment of estrogen-sensitive disease
|
|
IL145838A
(en)
|
2000-10-16 |
2008-11-03 |
Pfizer Prod Inc |
Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
|
|
AU2002221269A1
(en)
|
2000-10-19 |
2002-04-29 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
IL154984A0
(en)
|
2000-10-19 |
2003-10-31 |
Merck & Co Inc |
Estrogen receptor modulators
|
|
US6750213B2
(en)
|
2000-10-19 |
2004-06-15 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
JP2004519490A
(ja)
|
2001-01-26 |
2004-07-02 |
フアルマシア・イタリア・エツセ・ピー・アー |
エキセメスタンによるホルモン依存性異常症の組合せ治療方法
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
US20040082557A1
(en)
|
2001-01-26 |
2004-04-29 |
Wajszczuk Charles Paul |
Methods for treating estrogen-dependent disorders
|
|
GB2374412A
(en)
|
2001-04-11 |
2002-10-16 |
Karobio Ab |
Hypertension treatment and assay
|
|
WO2003016270A2
(en)
|
2001-08-11 |
2003-02-27 |
Bristol-Myers Squibb Pharma Company |
Selective estrogen receptor modulators
|
|
CA2459943A1
(en)
|
2001-09-21 |
2003-04-03 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
|
WO2003029268A1
(en)
|
2001-10-03 |
2003-04-10 |
Merck & Co., Inc. |
Androstane 17-beta-carboxamides as androgen receptor modulators
|
|
IL161162A0
(en)
|
2001-10-10 |
2004-08-31 |
Pharmacia Italia Spa |
Methods for preventing and treating bone loss with steroid compounds
|
|
JP2005509629A
(ja)
|
2001-10-19 |
2005-04-14 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターおよびその使用方法
|
|
US7105679B2
(en)
*
|
2001-12-19 |
2006-09-12 |
Kanojia Ramesh M |
Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
|
|
IL162295A0
(en)
*
|
2001-12-19 |
2005-11-20 |
Ortho Mcneil Pharm Inc |
Tetracyclic heterocompounds as estrogen receptor modulators
|
|
EP1465619A1
(en)
|
2002-01-14 |
2004-10-13 |
Nordic Bioscience A/S |
Suppression of cartilage degradation via the estrogen receptor
|
|
WO2003070253A1
(en)
|
2002-02-21 |
2003-08-28 |
Pantarhei Bioscience B.V. |
Estrogenic component for treating decreased libido in women
|
|
HRP20040822A2
(en)
|
2002-03-13 |
2005-06-30 |
Merck & Co. Inc. |
Fluorinated 4-azasteroid derivatives as androgen receptor modulators
|
|
CN1625602A
(zh)
|
2002-03-13 |
2005-06-08 |
霍夫曼-拉罗奇有限公司 |
选择药物敏感性决定因子的方法和利用所选择的因子预测药物敏感性的方法
|
|
US20030225132A1
(en)
|
2002-04-11 |
2003-12-04 |
Dininno Frank P. |
Estrogen receptor modulators
|
|
ATE481397T1
(de)
|
2002-04-24 |
2010-10-15 |
Merck Sharp & Dohme |
Modulatoren des östrogenrezeptors
|
|
CA2484173A1
(en)
|
2002-04-30 |
2003-11-13 |
Merck & Co., Inc. |
4-azasteroid derivatives as androgen receptor modulators
|
|
IL165395A0
(en)
|
2002-06-25 |
2006-01-15 |
Wyeth Corp |
Use of thio-oxubdile derivatives in treatment of hormone-related conditions
|
|
CN1662241A
(zh)
|
2002-06-25 |
2005-08-31 |
惠氏公司 |
环硫代氨基甲酸酯衍生物在治疗与激素有关的病症中的用途
|
|
EP1581217A4
(en)
|
2002-11-01 |
2007-07-11 |
Merck & Co Inc |
CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
|
|
WO2004091488A2
(en)
|
2003-04-14 |
2004-10-28 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
|
ES2394782T3
(es)
|
2003-05-07 |
2013-02-05 |
Osteologix A/S |
Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos
|
|
CA2524409C
(en)
|
2003-05-07 |
2011-12-20 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
US20040248989A1
(en)
|
2003-06-05 |
2004-12-09 |
Risto Santti |
Method for the treatment or prevention of lower urinary tract symptoms
|
|
CA2530025A1
(en)
|
2003-06-30 |
2005-01-20 |
William P. Dankulich |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
JP2007521297A
(ja)
|
2003-06-30 |
2007-08-02 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
|
|
AU2004255749B2
(en)
|
2003-06-30 |
2008-12-18 |
Merck Sharp & Dohme Corp. |
17-acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
US7329750B2
(en)
|
2003-06-30 |
2008-02-12 |
Merck & Co., Inc. |
17-Acetamido-4-azasteroid derivatives as androgen receptor modulators
|
|
CA2537663A1
(en)
|
2003-09-10 |
2005-03-24 |
Merck & Co., Inc. |
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
AU2004272007B2
(en)
|
2003-09-10 |
2009-05-28 |
Merck Sharp & Dohme Corp. |
17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
|
|
DE602004014806D1
(de)
|
2003-10-08 |
2008-08-14 |
Smithkline Beecham Corp |
Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors
|
|
EP1696925A4
(en)
|
2003-10-31 |
2009-11-18 |
Merck & Co Inc |
21-Heterocyclic 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS
|
|
EP1713770A1
(en)
|
2004-01-29 |
2006-10-25 |
Eli Lilly And Company |
Selective estrogen receptor modulators
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
WO2005123130A2
(en)
|
2004-06-17 |
2005-12-29 |
Osteologix A/S |
Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
|
|
US20090035315A1
(en)
|
2004-06-17 |
2009-02-05 |
Stephan Christgau |
Method of Improving Treatments in Rheumatic and Arthritic Diseases
|
|
EP1786408A4
(en)
|
2004-09-03 |
2010-07-28 |
Hormos Medical Ltd |
USE OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR IN THE MANUFACTURE OF A PHARMACEUTICAL PREPARATION USED IN A METHOD OF TREATING OR PREVENTING ENDROGENIC INJURIES
|
|
US8835413B2
(en)
|
2004-10-20 |
2014-09-16 |
Endorecherche, Inc. |
Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
|
|
WO2006084937A1
(en)
|
2005-02-14 |
2006-08-17 |
Leskelae Hannu-Ville |
Method for diagnosing and treating women with increased response to hormonal replacement therapy
|
|
US20070078114A1
(en)
|
2005-09-02 |
2007-04-05 |
Myriad Genetics, Incorporated |
Combination therapy for alzheimer's disease and other diseases
|
|
WO2007098090A2
(en)
|
2006-02-17 |
2007-08-30 |
Novacea, Inc. |
Treatment of hyperproliferative diseases with n-oxides of estrogen receptor modulators
|
|
US20080268041A1
(en)
|
2007-04-23 |
2008-10-30 |
Jens Hoffmann |
Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
|
|
DE102007026877A1
(de)
|
2007-06-08 |
2008-12-11 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
|
|
WO2009143309A2
(en)
|
2008-05-21 |
2009-11-26 |
Trustees Of Dartmouth College |
Female reproductive tract and anal prophylaxes
|
|
WO2010107474A1
(en)
|
2009-03-16 |
2010-09-23 |
The Research Foundation Of State University Of New York |
Antiestrogens for breast cancer therapy
|
|
US20100317635A1
(en)
|
2009-06-16 |
2010-12-16 |
Endorecherche, Inc. |
Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
|
|
HUE033581T2
(hu)
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
CA2819299A1
(en)
|
2010-12-24 |
2012-06-28 |
Merck Sharp & Dohme B.V. |
N-substituted azetidine derivatives
|
|
JP6112625B2
(ja)
|
2011-12-14 |
2017-04-12 |
セラゴン ファーマシューティカルズ，インク． |
フッ素化したエストロゲン受容体モジュレーターおよびその使用
|
|
PE20150099A1
(es)
|
2011-12-16 |
2015-01-30 |
Olema Pharmaceuticals Inc |
Compuestos novedosos de benzopirano, composiciones y usos de los mismos
|